Ampio Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants
Published: Aug 08, 2018
Ampio Pharmaceuticals, Inc., (NYSE MKT: AMPE) ("Ampio"), a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the securities in the proposed offering are to be sold by Ampio, with the net proceeds to be used for working capital and general corporate purposes, including continued preclinical development of Ampion and funding an Ampion clinical trial, if required.
Canaccord Genuity is acting as sole book-running manager for the proposed offering.
The sale of the common stock and the accompanying warrants to purchase shares of common stock is being offered by Ampio pursuant to a shelf registration statement on Form S-3 (Registration No. 333-217094), which was declared effective by the Securities and Exchange Commission (the "SEC") on April 20, 2017. A preliminary prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may also be obtained by contacting Canaccord Genuity LLC, 99 High Street, Suite 1200, Boston, MA 02110, Attn: Syndicate Department, by telephone at (617) 371-3900 or by e-mail at firstname.lastname@example.org. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.
This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities law of any such state or jurisdiction.
About Ampio Pharmaceuticals:
Forward Looking Statements:
View original content with multimedia:http://www.prnewswire.com/news-releases/ampio-pharmaceuticals-inc-announces-proposed-public-offering-of-common-stock-and-warrants-300694375.html
SOURCE Ampio Pharmaceuticals, Inc.
Company Codes: AMEX:AMPE